60 Degrees Pharmaceuticals (SXTP) Liabilities and Shareholders Equity (2022 - 2026)

60 Degrees Pharmaceuticals (SXTP) has reported Liabilities and Shareholders Equity for 5 consecutive years, with $6.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 13.14% year-over-year to $6.8 million; the TTM figure through Mar 2026 stood at $23.0 million (down 2.06% YoY), while the FY2025 annual figure was $5.4 million, down 6.83% from the prior year.
• Liabilities and Shareholders Equity rose to $6.8 million in Q1 2026 per SXTP's latest filing, from $5.4 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $9.2 million in Q3 2023 and bottomed at $1.3 million in Q4 2022.
• Historically, Liabilities and Shareholders Equity has averaged $6.2 million across 5 years, with a median of $6.7 million in 2025.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity surged 500.04% — and 2024, when it tumbled 41.2%.
• 60 Degrees Pharmaceuticals' Liabilities and Shareholders Equity stood at $1.3 million in 2022, then soared by 500.04% to $7.8 million in 2023, then dropped by 26.01% to $5.8 million in 2024, then retreated by 6.83% to $5.4 million in 2025, then increased by 26.04% to $6.8 million in 2026.
• Business Quant data shows SXTP's Liabilities and Shareholders Equity at $6.8 million in Q1 2026, $5.4 million in Q4 2025, and $6.7 million in Q3 2025.